NYSE
BDX

Becton Dickinson and Company

Medical Instruments & Supplies
Healthcare

Prices are adjusted according to historical splits.

Becton Dickinson and Company Stock Price

Vitals

Today's Low:
$262.7396
Today's High:
$267.32
Open Price:
$266.99
52W Low:
$214.2707
52W High:
$266.7
Prev. Close:
$267.18
Volume:
1111318

Company Statistics

Market Cap.:
$72.14 billion
Book Value:
90.442
Revenue TTM:
$18.81 billion
Operating Margin TTM:
13.5%
Gross Profit TTM:
$8.61 billion
Profit Margin:
8.6%
Return on Assets TTM:
2.91%
Return on Equity TTM:
6.56%

Company Profile

Becton Dickinson and Company had its IPO on 1987-01-01 under the ticker symbol BDX.

The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Becton Dickinson and Company has a staff strength of 77,000 employees.

Stock update

Shares of Becton Dickinson and Company opened at $266.99 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $262.74 - $267.32, and closed at $263.7.

This is a -1.3% slip from the previous day's closing price.

A total volume of 1,111,318 shares were traded at the close of the day’s session.

In the last one week, shares of Becton Dickinson and Company have slipped by -4.98%.

Becton Dickinson and Company's Key Ratios

Becton Dickinson and Company has a market cap of $72.14 billion, indicating a price to book ratio of 2.8477 and a price to sales ratio of 3.762.

In the last 12-months Becton Dickinson and Company’s revenue was $18.81 billion with a gross profit of $8.61 billion and an EBITDA of $4.81 billion. The EBITDA ratio measures Becton Dickinson and Company's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Becton Dickinson and Company’s operating margin was 13.5% while its return on assets stood at 2.91% with a return of equity of 6.56%.

In Q1, Becton Dickinson and Company’s quarterly earnings growth was a positive 1.8% while revenue growth was a positive 1.5%.

Becton Dickinson and Company’s PE and PEG Ratio

Forward PE
20.5761
Trailing PE
46.0962
PEG
2.3141

Its diluted EPS in the last 12-months stands at $5.51 per share while it has a forward price to earnings multiple of 20.5761 and a PEG multiple of 2.3141. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Becton Dickinson and Company’s profitability.

Becton Dickinson and Company stock is trading at a EV to sales ratio of 4.6127 and a EV to EBITDA ratio of 19.7374. Its price to sales ratio in the trailing 12-months stood at 3.762.

Becton Dickinson and Company stock pays annual dividends of $3.56 per share, indicating a yield of 1.47% and a payout ratio of 32%.

Balance sheet and cash flow metrics

Total Assets
$54.39 billion
Total Liabilities
$7.30 billion
Operating Cash Flow
$-233000000.00
Capital Expenditure
$181 million
Dividend Payout Ratio
32%

Becton Dickinson and Company ended 2024 with $54.39 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $54.39 billion while shareholder equity stood at $25.69 billion.

Becton Dickinson and Company ended 2024 with $0 in deferred long-term liabilities, $7.30 billion in other current liabilities, 365000000.00 in common stock, $15.56 billion in retained earnings and $24.78 billion in goodwill. Its cash balance stood at $1.98 billion and cash and short-term investments were $1.99 billion. The company’s total short-term debt was $2,214,000,000 while long-term debt stood at $16.01 billion.

Becton Dickinson and Company’s total current assets stands at $9.59 billion while long-term investments were $0 and short-term investments were $6.00 million. Its net receivables were $2.41 billion compared to accounts payable of $5.09 billion and inventory worth $3.66 billion.

In 2024, Becton Dickinson and Company's operating cash flow was $-233000000.00 while its capital expenditure stood at $181 million.

Comparatively, Becton Dickinson and Company paid $0.32 in dividends in 2024.

Other key metrics

Current Trading Price
$263.7
52-Week High
$266.7
52-Week Low
$214.2707
Analyst Target Price
$286.15

Becton Dickinson and Company stock is currently trading at $263.7 per share. It touched a 52-week high of $266.7 and a 52-week low of $266.7. Analysts tracking the stock have a 12-month average target price of $286.15.

Its 50-day moving average was $270.91 and 200-day moving average was $253.09 The short ratio stood at 2.2 indicating a short percent outstanding of 0%.

Around 35.3% of the company’s stock are held by insiders while 8974.7% are held by institutions.

Frequently Asked Questions About Becton Dickinson and Company

The stock symbol (also called stock or share ticker) of Becton Dickinson and Company is BDX

The IPO of Becton Dickinson and Company took place on 1987-01-01

Similar Industry Stocks (Medical Instruments & Supplies)

Last Price
Chg
Chg%
$23.2
-0.08
-0.34%
$0.87
-0.02
-1.87%
Kone Oyj ADR (KNYJY)
$22.09
0.28
+1.28%
$217.6
-11.35
-4.96%
$0.01
-0
-25%
$8.05
-0.36
-4.28%
CorVel Corp (CRVL)
$198.14
-3.53
-1.75%
$30.7
-0.5
-1.6%
$114.95
-6.8
-5.59%
$1.44
0.07
+5.11%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Address

1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880